research Multiple Sclerosis: Side Effects of Interferon Beta Therapy and Their Management
The article suggests managing interferon beta therapy side effects in MS with dose adjustments, medications, and patient education.
Search
for
Sort by
Research
30 / 1000+ results research Altered Dermal Fibroblasts in Systemic Sclerosis Display Podoplanin and CD90
Fibroblast changes in systemic sclerosis may help understand disease severity and treatment.
research Disease Modifying Agent Related Skin Reactions in Multiple Sclerosis: Prevention, Assessment, and Management
The article concludes that proper injection techniques and patient education can prevent serious skin reactions from multiple sclerosis medications.
research Multiple Sclerosis Disease-Modifying Therapies: Adverse Effect Surveillance and Management
The document concludes that managing side effects of MS therapies is crucial for treatment success and patient adherence.
research Birt–Hogg–Dubé Syndrome: A Histopathological Pitfall With Similarities to Tuberous Sclerosis
Birt–Hogg–Dubé Syndrome requires genetic testing for accurate diagnosis due to its similarities with tuberous sclerosis.
research Transient Hair Loss During Treatment with Dimethyl Fumarate for Multiple Sclerosis
Dimethyl-fumarate may cause temporary hair loss.
research Vitiligo-Like Depigmentation With Perifollicular Pigment Retention in Systemic Sclerosis Treated Successfully With Suplatast Tosilate
Suplatast tosilate successfully treated a woman's systemic sclerosis symptoms.
research Alopecia Universalis After Alemtuzumab Treatment for Multiple Sclerosis: A Two-Year Follow-Up of Two Patients
Two patients developed complete hair loss after Alemtuzumab treatment for MS, with no regrowth after two years.
research Acne Necrotica in a Woman with Systemic Lupus Erythematosus and Systemic Sclerosis
A woman with lupus and systemic sclerosis developed severe acne that didn't improve with treatment and died from pneumonia and septic shock.
research Ayurvedic Management of Systemic Sclerosis: A Case Report
Ayurvedic treatments can improve symptoms and quality of life for systemic sclerosis patients.
research High Fat Diet and the Adipocyte to Myofibroblast Transition: Implications for Systemic Sclerosis Cutaneous Fibrosis
A high fat lard diet may protect against skin fibrosis and affect hair growth.
research Skin Complications Associated With Interferon-Beta Treatment In Patients With Multiple Sclerosis, Tehran In 2021
Interferon beta treatment in MS patients can cause skin reactions and increased hair loss.
research Multiple Sclerosis and Alopecia Areata: Drug-Induced Alopecia Areata or Coexisting Autoimmune Phenomena?
Some multiple sclerosis treatments may trigger hair loss conditions like alopecia areata.
research BH03: Systemic Sclerosis and Frontal Fibrosing Alopecia: A Novel Combination of Scarring Alopecia
A woman with systemic sclerosis developed a unique scarring hair loss combining features of systemic sclerosis and frontal fibrosing alopecia.
research Severe Alopecia Complicating Systemic Sclerosis
A woman with severe hair loss due to systemic sclerosis regrew her hair in 4 months using a combination of treatments.
research Increased Cathepsin B Expression in Cultured Tuberous Sclerosis Skin Tumor Cells and Patient Tumor Tissues
Skin tumor cells in patients with tuberous sclerosis have higher levels of a protein called cathepsin B.
research Tuberous Sclerosis: Clinical Findings in 57 Patients
Most patients with Tuberous sclerosis had neurological or skin issues, and over half had psychiatric problems.
research Teriflunomide and Its Mechanism of Action in Multiple Sclerosis
Teriflunomide helps reduce multiple sclerosis symptoms and is safe for most patients.
research Teriflunomide in Multiple Sclerosis: An Update
Teriflunomide effectively reduces relapses and disability in MS and has a manageable safety profile.
research Real-World Observational Evaluation of Hair Thinning in Patients with Multiple Sclerosis Receiving Teriflunomide: Is It an Issue in Clinical Practice?
Hair thinning is a common but generally mild and reversible side effect of teriflunomide in multiple sclerosis patients.
research Skin Lesions in a Daclizumab-Treated Patient with Multiple Sclerosis
A patient with multiple sclerosis developed skin reactions after Daclizumab treatment, requiring more data on the drug's effects.
research Disease-Modifying Therapy in Multiple Sclerosis: Strategies for Optimizing Management
A comprehensive approach to educating patients and managing side effects is crucial for improving adherence to multiple sclerosis treatments and patient quality of life.
research Teriflunomide (Aubagio) for the Treatment of Multiple Sclerosis
Teriflunomide is an effective and generally safe oral treatment for relapsing MS, reducing relapses and slowing disability progression.
research Experimental Production of Cutaneous Calcinosis and Sclerosis with Dihydrotachysterol (AT-10)
Giving dihydrotachysterol to mother rats caused skin hardening and bone issues in their babies through milk.
research The Shifting Landscape of Disease-Modifying Therapies for Relapsing Multiple Sclerosis
New treatments for relapsing multiple sclerosis are more effective and convenient but have higher risks of serious side effects.
research Capillaroscopic Patterns in Patients with Systemic Sclerosis, Psoriasis, and Alopecia and Their Correlations with Serum Concentrations of Several Angiogenic Markers
Blood vessel patterns in skin diseases relate to certain blood markers in systemic sclerosis but not in psoriasis or psoriatic arthritis, and may indicate circulation issues in alopecia.
research Teriflunomide: A Once-Daily Oral Medication for the Treatment of Relapsing Forms of Multiple Sclerosis
Teriflunomide effectively reduces relapse rates and disease progression in multiple sclerosis but is not safe for use during pregnancy.
research Teriflunomide in Patients with Relapsing-Remitting Forms of Multiple Sclerosis
Teriflunomide is effective and generally safe for treating relapsing-remitting multiple sclerosis.
research Teriflunomide: A Novel Oral Treatment for Relapsing Multiple Sclerosis
Teriflunomide is an effective and safe first-line oral treatment for relapsing multiple sclerosis.
research Does Post-Void Residual Volume Predict Worsening Urological Symptoms in Patients with Multiple Sclerosis?
Post-void residual volume does not predict worsening urological symptoms in multiple sclerosis patients.